Random PostsCompany Watchlist – April 13-17/09BioElectronics Corp. (OTC:BIEL) – A Doubled Edged SwordHemispherx (AMEX:HEB) Seeks Rebound: Phase 6 Flu PandemicNSPT is a buy
Topics: us hyperinflation, Videos, world hyperinflation

{"title":"Hyperinflation Nation \u2013 The Fall of the USD","post_url":"http:\/\/www.stockshaven.com\/hyperinflation-nation-the-fall-of-the-usd\/","feed_url":"http:\/\/feeds.feedburner.com\/stockshaven","author":null,"date":"2009-06-29 10:13:21","summary":"Random PostsCompany Watchlist – April 13-17\/09BioElectronics Corp. (OTC:BIEL) – A Doubled Edged SwordHemispherx (AMEX:HEB) Seeks Rebound: Phase 6 Flu PandemicNSPT is a buy"}

Access Pharmaceuticals Inc.(OTC:ACCP)At approximately 5:00pm EST, 6/23/09, StocksHaven Investments began the call conference scheduled with Director & CEO of Access Pharmaceuticals Inc., Mr. Jeffrey B. Davis, whom was also joined by Director &...
Topics: access pharma, access pharma conference call, ACCP, accp mugard, Conference Call

{"title":"Conference Call \u2013 Access Pharmaceuticals Inc.","post_url":"http:\/\/www.stockshaven.com\/conference-call-access-pharmaceuticals-inc\/","feed_url":"http:\/\/feeds.feedburner.com\/stockshaven","author":null,"date":"2009-06-24 10:32:56","summary":"Access Pharmaceuticals Inc.(OTC:ACCP)At approximately 5:00pm EST, 6\/23\/09, StocksHaven Investments began the call conference scheduled with Director & CEO of Access Pharmaceuticals Inc., Mr. Jeffrey B. Davis, whom was also joined by Director &..."}

BioElectronics Corporation(OTC:BIEL)BioElectronics is a company which is plagued by a poor financial balance sheet, unaudited filings and barely sustainable ongoing operations with its current expenses constantly exceeding revenues, however is it worth...
Topics: allay product, BIEL, biel pdufa, bioelectronics corporation, bioelectronics fda, NEPH, Stock Picks, TM

{"title":"BioElectronics Corp. (OTC:BIEL) - A Doubled Edged Sword","post_url":"http:\/\/www.stockshaven.com\/bioelectronics-corp-otcbiel-a-doubled-edged-sword\/","feed_url":"http:\/\/feeds.feedburner.com\/stockshaven","author":null,"date":"2009-06-19 08:09:05","summary":"BioElectronics Corporation(OTC:BIEL)BioElectronics is a company which is plagued by a poor financial balance sheet, unaudited filings and barely sustainable ongoing operations with its current expenses constantly exceeding revenues, however is it worth..."}

Nephros, Inc. (OTC: NEPH)A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with...
Topics: ESRD, HDF, NEPH, neph fda medical, nephros medical devices, pdufa nephros stock, Stock Picks

{"title":"Nephros (OTC:NEPH): Three FDA Decisions, One Company","post_url":"http:\/\/www.stockshaven.com\/nephros-otcneph-three-fda-decisions-one-company\/","feed_url":"http:\/\/feeds.feedburner.com\/stockshaven","author":null,"date":"2009-06-17 18:28:17","summary":"Nephros, Inc. (OTC: NEPH)A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with..."}

Nuvo Research Inc.(TSE:NRI)Nuvo Research Inc. has been red hot this past month and is expected to continue. StocksHaven Investments has identified Nuvo Research as its top candidate for undervalued biotech pre-PDUFA. With a current PPS below $1.00 CAD,...
Topics: ACR, fda pennsaid, NRI, nuvo research inc, nuvo research pdufa, OA, POHA, Stock Picks

{"title":"Third Time\u2019s A Charm For Nuvo Research (TSE:NRI)","post_url":"http:\/\/www.stockshaven.com\/nuvo-research-fda-pennsaid-tse-nri\/","feed_url":"http:\/\/feeds.feedburner.com\/stockshaven","author":null,"date":"2009-06-16 07:42:25","summary":"Nuvo Research Inc.(TSE:NRI)Nuvo Research Inc. has been red hot this past month and is expected to continue. StocksHaven Investments has identified Nuvo Research as its top candidate for undervalued biotech pre-PDUFA. With a current PPS below $1.00 CAD,..."}